Principles of Basic Sciences Related to Cancer

  • E. Edmund Kim
  • David J. Yang


The evidence that cancer has a genetic basis originates from three observations: first, carcinogens cause DNA mutations; second, tumors frequently display specific chromosomal abnormalities; and third, in rare cancer syndromes, a predisposition to the development of cancer is inherited [1]. Oncogenes are predominantly components of pathways that activate cell division in response to growth factor stimulation. Malignant transformation can be a consequence of mutations that increase their activity or expression. Mutations that inactivate tumor suppressor genes are commonly found in human tumor samples. The role of these genes is to encode proteins that constrain proliferation, in some cases by direct interactions with members of the oncogene family.


Major Histocompatibility Complex Chronic Myelogenous Leukemia Major Histocompatibility Complex Molecule Iymph Node Normal Connective Tissue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ellis MJC, Sikora K. Molecular biology of cancer. In: Cox TM, Sinclair J, eds. Molecular Biology in Medicine. London: Blackwell Science, 1997:149–171.Google Scholar
  2. 2.
    Lewin N. Genes IV, 4th Ed. Oxford: Oxford University Press, 1990.Google Scholar
  3. 3.
    Atchison ML. Enhancers: mechanisms of action and cell specificity. Annu Rev Cell Biol 1988;4: 127–137.PubMedCrossRefGoogle Scholar
  4. 4.
    Laskey RA, Earnshaw WC. Nucleosome assembly. Nature (Lond) 1980;286:763–768.CrossRefGoogle Scholar
  5. 5.
    Wang JC. DNA topoisomerases. Annu Rev Biochem 1985;54:665–671.PubMedCrossRefGoogle Scholar
  6. 6.
    Smith HO. Nucleotide sequence specificity of restriction endonucleases. Science 1979;205:455–457.PubMedCrossRefGoogle Scholar
  7. 7.
    Cochran BH, Reffel AC, Stiles CD. Molecular cloning of gene sequences regulated by plateletderived growth factor. Cell 1983;33:939–943.PubMedCrossRefGoogle Scholar
  8. 8.
    Maniatis T, Hardison RC, Lacy E, et al. The isolation of structural genes from libraries of eukaryotic DNA. Cell 1978;15:687–692.PubMedCrossRefGoogle Scholar
  9. 9.
    Southern EM. Detection of specific sequences among DNA fragments separated by gel elec-trophoresis. J Mol Biol 1975;98:503–508.PubMedCrossRefGoogle Scholar
  10. 10.
    White R, Woodward S, Leppert M, et al. A closely linked genetic marker for cystic fibrosis. Nature (Lond) 1985;318:382–385.CrossRefGoogle Scholar
  11. 11.
    Knudson AG. Hereditary cancer, oncogenes, and antioncogenes. Cancer Res 1985;45:1437–1442.PubMedGoogle Scholar
  12. 12.
    Takahashi T, Nau MM, Chiba I, et al. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989;146:491–493.CrossRefGoogle Scholar
  13. 13.
    Saiki RK, Gelfand DH, Stoffel S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239:487–489.PubMedCrossRefGoogle Scholar
  14. 14.
    Maniatis T, Reed R. The role of small nuclear ribonucleoprotein particles in pre-mRNA splicing. Nature (Lond) 1987;325:673–679.CrossRefGoogle Scholar
  15. 15.
    Efstradiatis A, Kafatos FC, Maniatis T. The primary structure of rabbit β-globin mRNA as determined from cloned cDNA. Cell 1977;10: 571–575.CrossRefGoogle Scholar
  16. 16.
    Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979;76:4350–4354.PubMedCrossRefGoogle Scholar
  17. 17.
    Derynck R, Remaut E, Saman E, et al. Expression of human fibroblast interferon gene in Escherichia coli. Nature (Lond) 1980;287:193–195.CrossRefGoogle Scholar
  18. 18.
    Warburg O. On respiratory impairment in cancer cells. Science 1956;124:269–272.PubMedGoogle Scholar
  19. 19.
    Weinhouse S. Oxidative metabolism of neoplastic tissues. Adv Cancer Res 1955;3:269–273.PubMedCrossRefGoogle Scholar
  20. 20.
    Shapot VS. Some biochemical aspects of the relationship between the tumor and the host. Adv Cancer Res 1972;15:253–258.PubMedCrossRefGoogle Scholar
  21. 21.
    Greenstein JP. Some biochemical characteristics of morphologically separable cancers. Cancer Res 1956;16:641–645.PubMedGoogle Scholar
  22. 22.
    Potter VR. Biochemistry of cancer. In: Holland JF, Emil F III, eds. Cancer Medicine, 2nd Ed. Philadelphia: Lea & Febiger, 1982:133–143.Google Scholar
  23. 23.
    Walker PR, Potter VR. Isozyme studies on adult, regenerating precancerous and developing liver in relation to findings in hepatomas. Adv Enzyme Regul 1972;10:339–343.PubMedCrossRefGoogle Scholar
  24. 24.
    Tomaka T, Inamura K, Ann T, Taniuchi K. Multimolecular forms of pyruvate kinase and phosphofructokinase in normal and cancer tissue. Gann Monogr 1972;13:219–224.Google Scholar
  25. 25.
    Bollum FJ, Chang LMS. Terminal transferase in normal and leukemic cells. Adv Cancer Res 1986;47:37–41.PubMedCrossRefGoogle Scholar
  26. 26.
    Uriel J. Fetal characteristics of cancer. In: Becker FF, ed. Cancer: A Comprehensive Treatise, Vol. 3. New York: Plenum Press, 1975:21–30.Google Scholar
  27. 27.
    Helfta SA, Hefta LJF, Lee TD, et al. Carcinoembryonic antigen is anchored to membranes by covalent attachment to a glycosylphosphatidylinositol moiety: identification of the ethanolamine linkage site. Proc Natl Acad Sci USA 1988;85:4648–4652.CrossRefGoogle Scholar
  28. 28.
    Benchimol S, Fuks A, Jothy S, et al. Carcinoembryonic antigen; a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989;57:327–330.PubMedCrossRefGoogle Scholar
  29. 29.
    Robertson RP, Baylink DJ, Marini JJ, Adkinson HW. Elevated prostaglandins and suppressed parathyroid hormone associated with certain types of cancer. N Engl J Med 1975;293:1278–1281.CrossRefGoogle Scholar
  30. 30.
    Heber D, Chlebowski RT, Ishibashi DE, et al. Abnormalities in glucose and protein metabolism in noncachectic lung cancer patients. Cancer Res 1982;43:4815–4820.Google Scholar
  31. 31.
    Wang AM, Creasey AA, Ladner MB, et al. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 1985;228:149–152.PubMedCrossRefGoogle Scholar
  32. 32.
    Tabor CW, Tabor H. Polyamines. Annu Rev Biochem 1984;53:749–752.PubMedCrossRefGoogle Scholar
  33. 33.
    Luk GD, Baylin SB. ODC as a biologic marker in familial colonic polyposis. N Engl J Med 1984;311:80–83.PubMedCrossRefGoogle Scholar
  34. 34.
    Dice JF. Molecular determinants of protein halflives in eukaryotic cells. FASEB J 1987;1:349–354.PubMedGoogle Scholar
  35. 35.
    Bourne HR, DeFranco AL. Signal transduction and intracellular messengers. In: Weinberg RA, ed. Oncogenes and Molecular Origins of Cancer. New York: Cold Spring Harbor Laboratory Press, 1989:79–84.Google Scholar
  36. 36.
    Berger NA. Poly (ADP-ribose) in the cellular response to DNA damage. Radiat Res 1985;101: 4–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Hetts SW. To die or not to die. An overview of apoptosis and its role in disease. JAMA 1998; 270:300–307.CrossRefGoogle Scholar
  38. 38.
    Polyak K, Xia Y, Zweier JL, et al. A model for p53-induced apoptosis. Nature (Lond) 1997;389: 300–305.CrossRefGoogle Scholar
  39. 39.
    Jones PA, Buckley JD. The role of DNA methylation in cancer. Adv Cancer Res 1990; 54:1–6.PubMedCrossRefGoogle Scholar
  40. 40.
    de Bustros A, Nelkin BD, Silverman A, et al. The short arm of chromosome 11 is a hot spot for hypermethylation in human neoplasia. Proc Natl Acad Sci USA 1988;85:5693–5696.PubMedCrossRefGoogle Scholar
  41. 41.
    Vines RL, Coleman MS, Hutton JJ. Reappear-ance of terminal deoxynucleotidyl transferase containing cells in rat bone marrow following corticosteroid administration. Blood 1980;56: 501–506.PubMedGoogle Scholar
  42. 42.
    Itakomori S. Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 1989;52:259–261.Google Scholar
  43. 43.
    Paul WE (1989) The immune system: basic considerations. In: Paul WE, ed. Fundamental Immunology, 2nd Ed. New York: Raven Press, 1989:3–18.Google Scholar
  44. 44.
    Hodes RJ. T cell-mediated regulation: help and suppression. In: Paul WE, ed. Fundamental Immunology, 2nd Ed. New York: Raven Press, 1989:587–596.Google Scholar
  45. 45.
    Weiss A. Structure and function of the T cell antigen receptor. J Clin Invest 1990;86:1015–1021.PubMedCrossRefGoogle Scholar
  46. 46.
    Celis E, Tsai V, Crimi C. Induction of antitumor cytotoxic T lymphocytes in normal humans using primary cultures & synthetic peptide epitopes. Proc Natl Acad Sci USA 1993;91:2105–2109.CrossRefGoogle Scholar
  47. 47.
    Shu S, Chou T, Sakai K. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J Immunol 1989;143:746–748.Google Scholar
  48. 48.
    Miller AR, McBride WH, Hunt K, Economou JS. Cytokine-mediated gene therapy for cancer. Ann Surg Oncol 1994;1:436–450.PubMedCrossRefGoogle Scholar
  49. 49.
    Wallich R, Bulbuc N, Hammerling GJ, Katzar S, Segal S, Feldman M. Abrogation of metastatic properties of tumor cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature (Lond) 1985;3125:301–305.CrossRefGoogle Scholar
  50. 50.
    Dudley ME, Roopenian DC. Loss of a unique tumor antigen by cytotoxic T lymphocyte immunoselection from a 3-methylcholanthreneinduced mouse sarcoma reveals secondary unique and share antigens. J Exp Med 1996;184: 441–447.PubMedCrossRefGoogle Scholar
  51. 51.
    McLaughlin JP, Schlom J, Kantor JA, Griener JW. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res 1996;56:2361–2367.PubMedGoogle Scholar
  52. 52.
    Shu S, Plantz GE, Krauss JC, Chang AE. Tumor immunology. JAMA 1997;278:1972–1981.PubMedCrossRefGoogle Scholar
  53. 53.
    Canaani E, Marcelle C, Fainstein E. bcr-abl RNA in chronic myelogenous leukemia and lymphocytic leukemia. In: Deisseroth A, Arlinghaus RB, eds. Chronic Myelogenous Leukemia: Molecular Approaches to Research and Therapy, Part III. New York: Dekker, 1991:217–240.Google Scholar
  54. 54.
    Bocchia M, Korontsuit T, Xy Q. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996;87:3587–3592.PubMedGoogle Scholar
  55. 55.
    Cheever MA, Disis ML, Bernhard H. Immunity to oncogenic proteins. Immunol Rev 1995;145: 33–59.PubMedCrossRefGoogle Scholar
  56. 56.
    Houbiers JGA, Nijman HW, van der Burg SH. In vitro induction of human cytotoxic T lympho-cyte responses against peptides of mutated and wild type p53. Eur J Immunol 1993;23:2072–2077.PubMedCrossRefGoogle Scholar
  57. 57.
    Rosenberg SA, Lotze M, Yang JC. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989;210:474–484.PubMedCrossRefGoogle Scholar
  58. 58.
    Vieweg J, Gilboa E. Consideration for the use of cytokine-secreting tumor cell preparation for cancer treatment. Cancer Invest 1995;13:193–201.PubMedCrossRefGoogle Scholar
  59. 59.
    Chen L, Ashe S, Brady WA. Costimulation of antitumor immunity by the B7 counter receptor for the T lymphocyte molecule CD 28 and CTLA-4. Cell 1992;71:1093–1102.PubMedCrossRefGoogle Scholar
  60. 60.
    Murrey J, Rosenbaum MG, Sobol RE. Radioimmuno-imaging in malignant melanoma using In-111 labeled monoclonal antibody. Cancer Res 1985;45:2376–2381.Google Scholar
  61. 61.
    Kaminski MS, Zasadny RK, Francis IR. Iodine-131 anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974–1981.PubMedGoogle Scholar
  62. 62.
    Grimm EA, Robb RJ, Roth JA. Lymphokineactivated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood into lymphokine-activated killer cells. J Exp Med 1983;158:136.CrossRefGoogle Scholar
  63. 63.
    Rosenberg SA, Vannelli JR, Yang JC. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst 1994;86:1159–1166.PubMedCrossRefGoogle Scholar
  64. 64.
    Chang AE, Aruga A, Cameron MJ. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and IL-2. J Clin Oncol 1997;15:796–807.PubMedGoogle Scholar
  65. 65.
    Folkman J. Tumor angiogenesis. Adv Cancer Res 1985;43:175–180.PubMedCrossRefGoogle Scholar
  66. 66.
    Senger DR, Connolly DT, van de Water L, et al. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990;50:1774–1779.PubMedGoogle Scholar
  67. 67.
    Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors. A review. Cancer Res 1989;49:6449–6454.PubMedGoogle Scholar
  68. 68.
    Tannock IF, Rotin D. Acid pH in tumors and its potential for therapeutic exploitation. Cancer Res 1989;49:4373–4378.PubMedGoogle Scholar
  69. 69.
    Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146–149.PubMedCrossRefGoogle Scholar
  70. 70.
    Schnitt SJ, Silen W, Sadowsky NL, et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast. N Engl J Med 1988;318:898–902.PubMedCrossRefGoogle Scholar
  71. 71.
    Gleason DF. Histologic grade, clinical stage, and patient age in prostate cancer. Natl Cancer Inst Monogr 1988;7:15–19.Google Scholar
  72. 72.
    Elston CW. The assessment of histological differentiation in breast cancer. Aust N Z J Surg 1984;54:11–17.PubMedCrossRefGoogle Scholar
  73. 73.
    Hill RP. Tumor progression: potential role of unstable genomic changes. Cancer Metastasis Rev 1990;9:137–142.PubMedCrossRefGoogle Scholar
  74. 74.
    Nowell PC. Mechanisms of tumor progression. Cancer Res 1986;46:2203–2208.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • E. Edmund Kim
  • David J. Yang

There are no affiliations available

Personalised recommendations